ArticleCancers2018
A Multicenter Study to Assess
Article in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Efficacy of liquid biopsy for genetic mutations determination in non-small cell lung cancer: a systematic review on literatures.BMC cancer · 2025Pooled it
- Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions.Molecular diagnosis & therapy · 2020Pooled it
- Prognostic significance of six autoantibodies in esophageal squamous cell carcinoma: A prospective multi-institutional study.Annals of gastroenterological surgery · 2025Article
- Clinical Utility of ctDNA Analysis in Lung Cancer-A Review.Advances in respiratory medicine · 2025Review
- Blood collection tube and RNA purification method recommendations for extracellular RNA transcriptome profiling.Nature communications · 2025Article
- Observational
- Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer.ESMO open · 2022Review
- A clinician's handbook for using ctDNA throughout the patient journey.Molecular cancer · 2022Review
- The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer.British journal of cancer · 2021Review
- Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study.Drugs - real world outcomes · 2021Article
- When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review.Oncology and therapy · 2021Review
- Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data.Journal of cancer research and clinical oncology · 2020Article
- Article
- Utilization of Archived Plasma to Detect Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer Patients.Biopreservation and biobanking · 2019Article
- The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future.Current treatment options in oncology · 2019Review
- Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol.Cancers · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A multicenter study was performed to determine an optimal workflow for liquid biopsy in a clinical setting. In total, 549 plasma samples from 234 non-small cell lung cancer (NSCLC) patients were collected. Epidermal Growth Factor Receptor (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.